4-(5-allyl-6-methyl-2-(thiophen-2-yl)pyrimidin-4-ylamino)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(5-allyl-6-methyl-2-(thiophen-2-yl)pyrimidin-4-ylamino)benzoic acid
• 英文别名: 4-(5-allyl-6-methyl-2-thiophen-2-ylpyrimidin-4-ylamino)benzoic acid；4-[(6-methyl-5-prop-2-enyl-2-thiophen-2-ylpyrimidin-4-yl)amino]benzoic acid
• 化学式: C₁₉H₁₇N₃O₂S
• 分子量: 351.429
• InChiKey: SYBOCZJFEMYMOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  Methyl 4-[(6-methyl-5-prop-2-enyl-2-thiophen-2-ylpyrimidin-4-yl)amino]benzoate 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 4-(5-allyl-6-methyl-2-(thiophen-2-yl)pyrimidin-4-ylamino)benzoic acid
  参考文献：
  名称：

  Discovery of selective PDE4B inhibitors

  摘要：

  In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivatives afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, a selected compound exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.121

文献信息

• Pyrimidine derivatives
  申请人：Naganuma Kenji

  公开号：US20060293343A1

  公开（公告）日：2006-12-28

  The object of the invention is to provide a novel compound having an inhibitory action on PDE4 activity with fewer side effects. The invention provides a compound represented by the following general formula (1), possible stereoisomers thereof or racemates thereof, pharmacologically acceptable salts thereof, hydrates thereof, solvated compounds thereof, or prodrugs thereof,

  本发明的目的是提供一种对PDE4活性具有抑制作用且副作用较少的新型化合物。 该发明提供了一种由以下一般式（1）表示的化合物，其可能的立体异构体或外消旋体，其药理学上可接受的盐，水合物，溶剂化合物，或前药。
• WO2006/123639
  申请人：——

  公开号：——

  公开（公告）日：——
• SELECTIVE PDE4 B INHIBITION AND IMPROVEMENT IN COGNITION IN SUBJECTS WITH BRAIN INJURY
  申请人：TETRA DISCOVERY PARTNERS LLC

  公开号：US20140121221A1

  公开（公告）日：2014-05-01

  Provided herein are methods of improving cognitive ability or memory in a subject that has suffered a brain injury or spinal cord injury by administering a selective PDE4 B inhibitor.
• US8865723B2
  申请人：——

  公开号：US8865723B2

  公开（公告）日：2014-10-21
• Discovery of selective PDE4B inhibitors
  作者：Kenji Naganuma、Akifumi Omura、Naomi Maekawara、Masahiro Saitoh、Naoto Ohkawa、Takashi Kubota、Hiromitsu Nagumo、Toshiyuki Kodama、Masayoshi Takemura、Yuji Ohtsuka、Junji Nakamura、Ryuichi Tsujita、Koh Kawasaki、Hirotsugu Yokoi、Masashi Kawanishi

  DOI：10.1016/j.bmcl.2009.04.121

  日期：2009.6

  In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivatives afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, a selected compound exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast. (C) 2009 Elsevier Ltd. All rights reserved.